{
    "doi": "https://doi.org/10.1182/blood.V106.11.2149.2149",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=443",
    "start_url_page_num": 443,
    "is_scraped": "1",
    "article_title": "Recombinant Human FVIIa Reduces Heparin and Low Molecular Weight Heparin (LMWH)-Induced Bleeding in Rats. ",
    "article_date": "November 16, 2005",
    "session_type": "Poster Sessions",
    "topics": [
        "hemorrhage",
        "heparin",
        "low-molecular-weight heparin",
        "rats",
        "recombinant coagulation factor viia",
        "anticoagulants",
        "tinzaparin",
        "bleeding time procedure",
        "antidotes",
        "coumarins"
    ],
    "author_names": [
        "Brian Lauritzen",
        "Mikael Tranholm",
        "Peter B. Johansen",
        "Mirella Ezban"
    ],
    "author_affiliations": [
        [
            "Pharmacology Research 5, Novo Nordisk A/S, Ma\u030al\u00f8v, Denmark"
        ],
        [
            "Pharmacology Research 5, Novo Nordisk A/S, Ma\u030al\u00f8v, Denmark"
        ],
        [
            "Pharmacology Research 5, Novo Nordisk A/S, Ma\u030al\u00f8v, Denmark"
        ],
        [
            "Pharmacology Management, Novo Nordisk A/S, Ma\u030al\u00f8v, Denmark"
        ]
    ],
    "first_author_latitude": "55.754168899999996",
    "first_author_longitude": "12.299753099999998",
    "abstract_text": "Recombinant human FVIIa (rFVIIa, NovoSeven, Novo Nordisk A/S) is approved for treatment of bleeding in hemophilia patients with inhibitors. Recent data indicate that rFVIIa is useful in other bleeding conditions. Heparin and low molecular weight heparin (LMWH) are widely used for anticoagulant management of venous thromboembolic events. Both agents can however cause uncontrollable bleeding. While protamine can reverse the anticoagulant effect of heparin no effective antidote for LMWH is currently available. We have tested if rFVIIa was capable of reducing the bleeding caused by either heparin or LMWH in a rat tail bleeding model. We pre-treated rats with a single dose of either heparin (Heparin, Leo; 200 IU/kg; i.v.) or LMWH (tinzaparin; Innohep, Leo; 500 IU/kg; i.v.), which significantly prolonged total bleeding time following tail transection (table 1). Similarly, blood loss increased significantly by pre-treatment with heparin and tinzaparin (table 2). rFVIIa, intravenously injected 5 minutes after induction of tail bleeding in doses of 5, 10 and 20 mg/kg (n=8), dose-dependently reduced bleeding time of the heparin-induced bleeding, reaching statistical significance at 20 mg/kg (table 1). In accordance, blood loss decreased significantly by treatment with 10 and 20 mg/kg rFVIIa (table 2). A similar response was seen in the tinzaparin pre-treated animals with a dose-dependent decrease in bleeding time (table 1), and a significant decrease in blood loss at 10 and 20 mg/kg rFVIIa (table 2). Table 1. Total bleeding time (s)  Group . Heparin 200 IU/kg (n=8)# . Tinzaparin 500 IU/kg (n=9)# . Data are analyzed using Mann-Whitneys U-test (A-B) or Kruskall-Wallis test with Dunn\u2019s post-test (B-E). Asterisks indicate statistical significance at: *: p<0.05; **: p<0.01 and ***: p<0.001. #observation period 1800 s. A: No anticoagulant 293 \u00b1 68 542 \u00b1 180 B: Anticoag.+Vehicle 1668 \u00b1 83 ***vs. A 1800 \u00b1 0 ***vs. A C: Anticoag.+5 mg/kg rFVIIa 1194 \u00b1 182 1732 \u00b1 45 D: Anticoag.+10 mg/kg rFVIIa 1023 \u00b1 230 1483 \u00b1 152 E: Anticoag.+20 mg/kg rFVIIa 448 \u00b1 66 **vs. B 1038 \u00b1 206 *vs. B Group . Heparin 200 IU/kg (n=8)# . Tinzaparin 500 IU/kg (n=9)# . Data are analyzed using Mann-Whitneys U-test (A-B) or Kruskall-Wallis test with Dunn\u2019s post-test (B-E). Asterisks indicate statistical significance at: *: p<0.05; **: p<0.01 and ***: p<0.001. #observation period 1800 s. A: No anticoagulant 293 \u00b1 68 542 \u00b1 180 B: Anticoag.+Vehicle 1668 \u00b1 83 ***vs. A 1800 \u00b1 0 ***vs. A C: Anticoag.+5 mg/kg rFVIIa 1194 \u00b1 182 1732 \u00b1 45 D: Anticoag.+10 mg/kg rFVIIa 1023 \u00b1 230 1483 \u00b1 152 E: Anticoag.+20 mg/kg rFVIIa 448 \u00b1 66 **vs. B 1038 \u00b1 206 *vs. B View Large Table 2. Blood loss (nmol hemoglobin/ml)  Group . Heparin 200 IU/kg (n=8)# . Tinzaparin 500 IU/kg (n=9)# . Data are mean \u00b1 SEM. Data are analyzed after log transformation using Student\u2019s t-test (A-B) or one-way ANOVA with Bonferroni\u2019s post-test (B-E). Asterisks indicate statistical significance at: *: p<0.05; **: p<0.01 and ***: p<0.001. #observation period 1800 s. A: No anticoagulant 4.2 \u00b1 4.0 4.9 \u00b1 4.9 B: Anticoag.+Vehicle 53 \u00b1 19 **vs. A 151 \u00b1 37 ***vs. A C: Anticoag.+5 mg/kg rFVIIa 10.6 \u00b1 5.6 32.3 \u00b1 10.3 D: Anticoag.+10 mg/kg rFVIIa 0.73 \u00b1 0.34 **vs. B 7.7 \u00b1 2.8 ***vs. B E: Anticoag.+20 mg/kg rFVIIa 4.0 \u00b1 1.9 *vs. B 22.6 \u00b1 9.4 *vs. B Group . Heparin 200 IU/kg (n=8)# . Tinzaparin 500 IU/kg (n=9)# . Data are mean \u00b1 SEM. Data are analyzed after log transformation using Student\u2019s t-test (A-B) or one-way ANOVA with Bonferroni\u2019s post-test (B-E). Asterisks indicate statistical significance at: *: p<0.05; **: p<0.01 and ***: p<0.001. #observation period 1800 s. A: No anticoagulant 4.2 \u00b1 4.0 4.9 \u00b1 4.9 B: Anticoag.+Vehicle 53 \u00b1 19 **vs. A 151 \u00b1 37 ***vs. A C: Anticoag.+5 mg/kg rFVIIa 10.6 \u00b1 5.6 32.3 \u00b1 10.3 D: Anticoag.+10 mg/kg rFVIIa 0.73 \u00b1 0.34 **vs. B 7.7 \u00b1 2.8 ***vs. B E: Anticoag.+20 mg/kg rFVIIa 4.0 \u00b1 1.9 *vs. B 22.6 \u00b1 9.4 *vs. B View Large This study illustrates the pharmacological effect of rFVIIa in the presence of heparin and LMWH and the results indicate that rFVIIa may be an effective way to treat heparin and LMWH induced bleeding, however the dose requirements are specific for the rat and cannot be extrapolated to other species. Future studies will investigate the hemostatic effect of rFVIIa in bleedings induced by coumarin analogues, thrombin inhibitors, factor Xa inhibitors, and platelet inhibitors."
}